Drugs in development for viral hepatitis: Care and caution

Drugs

Volumn 71, Issue 3, 2011, Pages 263-271

  Pockros, Paul J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Boceprevir; Hepatitis C; Research and development; Telaprevir

Indexed keywords

ABT 333; ABT 450; ACH 1625; ACH 2684; ANA 598; ANTIVIRUS AGENT; BI 201335; BMS 790052; BMS 824393; BMS 850032; BOCEPREVIR; CASPASE INHIBITOR; CYCLOPHILIN INHIBITOR; DANOPREVIR; ERYTHROPOIETIN; FILIBUVIR; GI 5005; GS 5885; GS 9190; GS 9256; GS 9450; GS 9451; IDX 184; IDX 320; IDX 375; INTERLEUKIN 28B; INX 184; MK 5172; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NARLAPREVIR; NIVOCASAN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PPI 461; PROTEINASE INHIBITOR; PSI 7977; PSI 938; R 7128; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCY 635; TEGOBUVIR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIVIRAL THERAPY; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; OLIGOPEPTIDES; PROLINE;

HEPATITIS C VIRUS;

EID: 79951594372     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11587090-000000000-00000     Document Type: Review

References (21)

1. Roche Molecular Laboratories. Roche receives FDA approval for a second-generation hepatitis C viral load test [media release]. 2010 Oct 25 [online]. Available from URL: http://www.roche.com.
2. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
4. Thompson AJ, Muir AJ, Sulkowski MS, et al. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by Interleukin-28B genotype. Hepatology 2010; 52: 2243-4.
5. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-24.
6. LabCorp Service Announcement. LabCorp launches interleukin- 28 polymorphism (IL28B) genotype test to support individualized treatment decisions for patients with hepatitis C viral infection [media release]. 2010 Jul 12 [online]. Available from URL: http://www.labcorp.com.
7. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010 Oct; 139 (4): 1181-9.
8. The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2010. Hepatology 2010 Oct; 52 Suppl. S1: iiA-ivA, 1A-1352A.
9. Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 2006; 44: S10-3.
10. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [abstract]. Hepatology 2010; 52 Suppl. S1: 427A.
11. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa 2A and ribavirin for 24 or 48 weeks in treatment-na?̈ ve genotype 1 HCV patients who achieved and extended rapid viral response: final results of phase 3 ILLUMINATE study [abstract no. LB2]. Program and abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29-Nov 2; Boston (MA).
12. Poordad F, McCone J, Bacon BR, et al. Boceprevir combined with peginterferon alfa-2b/ribavirin for treatmentnaive patients with HCV genotype 1: SPRINT-2 final results [abstract no. LB4]. Program and abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29-Nov 2; Boston (MA).
13. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: High sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ ribavirin when re-treated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin [abstract]. Hepatology 2010; 52 Suppl. S1: 430A.
14. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: interim analysis of the EXTEND study [abstract]. Hepatology 2010; 52 Suppl. S1: 436A.
15. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-62.
16. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebocontrolled, dose-escalation trial. Lancet 2010; 376 (9751): 1467-75.
17. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment-naïve, genotype 1 HCV subjects [abstract no. LB1]. Program and abstracts of the 61st AnnualMeeting of the American Association for the Study of Liver Diseases; 2010 Oct 29-Nov 2; Boston (MA).
18. Guedj J, Rong L, Dahari H, et al. A perspective on modeling hepatitis C virus infection. J Viral Hepat 2010 Dec; 17 (12): 825-33.
19. Struble K. Clinical trials design: experimental HCV drugs for HIV/HCV co-infected people: FDA perspectives on clinical trial design for new HCV products, early access [abstract and oral presentation]. European AIDS Treatment Group Meeting; 2009 Nov 21; Brussels.
20. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011 Feb; 140 (2): 459-68.e1.
21. Vertex Pharmaceuticals. 65% of people whose prior treatment for hepatitis C was unsuccessful achieved SVR (viral cure) with telaprevir-based therapy in phase 3 REALIZE study [media release]. 2010 Sep 7 [online]. Available from URL: http://www.vertex.com